Best Cell & Gene Therapy CDMOs in Europe

Last updated: 2026-10-06 · updated as new inspection, certificate, and trial data enters the platform

← All Cell & Gene Therapy CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs tracked

Fully scored

With FDA records

FDA inspections

279

EMA/MHRA GMP certs

Warning letters

For European-manufactured cell & gene therapy programs, Novartis, Takeda, and Merck KGaA / MilliporeSigma (CDMO) lead CDMO Signal's ranking of cell & gene therapy CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 105 scored cell & gene therapy CDMOs to 8 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.

For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).

FDA inspection outcomes across these CDMOs: 22 NAI (no action), 35 VAI (voluntary action), 4 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (60), Austria (56), United States (48), Denmark (35), Germany (29).

Last updated 2026-10-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	Novartis Basel, Switzerland	87.1	93.1	16 insp · 67 GMP	—	135 programs
2	TK Takeda Boston, MA · Zurich, CH	81.9	99.6	4 insp · 18 GMP	—	100 programs
3	MK Merck KGaA / MilliporeSigma (CDMO) Darmstadt, DE · St. Louis, MO	81.8	98.7	2 insp · 2 GMP	—	22 programs
4	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	78.6	100.0	2 insp · 23 GMP	Available	2 programs
5	OX Oxford Biomedica Oxford, United Kingdom	76.2	100.0	0 insp · 13 GMP	Available	7 programs
6	Lonza Basel, Switzerland	76.0	95.7	2 insp · 8 GMP	—	1 programs
7	MB Miltenyi Biotec Bergisch Gladbach, Germany	73.0	100.0	0 insp · 2 GMP	—	8 programs
8	RT ReiThera Rome, IT	71.1	100.0	0 insp · 4 GMP	—	1 programs
9	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	90.9	98.3	8 insp · 11 GMP	Limited	0 programs
10	RP ReciBioPharm Keele, UK · Sodertalje, SE	88.0	100.0	0 insp · 3 GMP	—	0 programs
11	FD FUJIFILM Diosynth Biotechnologies Research Triangle, NC · Holly Springs, NC · Hillerod, DK	84.8	100.0	0 insp · 23 GMP	Expanding	0 programs
12	MN Minaris Advanced Therapies Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP	83.3	99.6	1 insp · 6 GMP	Limited	0 programs
13	SC SCTbio Prague, Czech Republic	81.6	100.0	0 insp · 5 GMP	—	0 programs
14	EF Eurofins CDMO Planegg, DE · San Diego, CA	81.6	100.0	5 insp · 0 GMP	—	0 programs
15	RC RoslinCT Edinburgh, UK · Hopkinton, MA	80.3	99.0	1 insp · 1 GMP	Available	0 programs
16	CF CELLforCURE (SEQENS) Les Ulis, FR	80.3	100.0	0 insp · 4 GMP	—	0 programs
17	BR BioReliance (Merck) Glasgow, UK · Rockville, MD	80.2	97.1	4 insp · 8 GMP	—	0 programs
18	SK SK pharmteco Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.	79.5	100.0	—	Available	0 programs
19	AA Ascend Advanced Therapies London, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
20	NG NecstGen Leiden, NL	78.1	100.0	0 insp · 1 GMP	—	0 programs
21	ET Exothera Jumet, BE	78.1	100.0	0 insp · 4 GMP	—	0 programs
22	PG ProBioGen Berlin, DE	78.1	100.0	0 insp · 4 GMP	—	0 programs
23	OR Ori Biotech London, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
24	CE Celonic Basel, Switzerland	78.1	100.0	0 insp · 1 GMP	—	0 programs
25	XP eXmoor Pharma Bristol, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
26	AD Advent Bioservices London, United Kingdom	78.1	100.0	0 insp · 2 GMP	—	0 programs
27	BV Biovian Turku, Finland	78.0	99.8	1 insp · 4 GMP	—	0 programs
28	VG Viralgen Vector Core San Sebastián, Spain	76.8	100.0	0 insp · 4 GMP	Available	0 programs
29	SY Symbiosis Pharmaceutical Services Stirling, United Kingdom	76.8	100.0	1 insp · 9 GMP	—	0 programs
30	CY Cell-Easy Toulouse, FR	76.8	100.0	0 insp · 2 GMP	—	0 programs
31	CN Cellin Technologies Luxembourg, LU	76.8	100.0	0 insp · 1 GMP	—	0 programs
32	HH HiTech Health London, United Kingdom	76.8	100.0	0 insp · 9 GMP	—	0 programs
33	CG Cytiva (Mfg Services) Marlborough, MA · Uppsala, SE	74.0	—	—	—	0 programs
34	Catalent Bagsværd, Denmark (operating under Novo Holdings)	73.1	74.9	12 insp · 37 GMP	—	0 programs
35	CA Catalent (Novo Holdings) Harmans, MD · Gosselies, BE	73.1	74.9	1 insp · 0 GMP	Available	0 programs
36	LZ Lonza Biologics Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH	73.0	95.7	1 insp · 0 GMP	Limited	0 programs
37	RA Recipharm Advanced Bio Stockholm, Sweden	63.0	—	—	—	0 programs
38	AB Asklepios BioPharmaceutical (AskBio) Research Triangle, NC · San Sebastian, ES	61.8	—	—	—	10 programs
39	CP Cell and Gene Therapy Catapult Stevenage, United Kingdom	59.0	—	—	—	0 programs
40	EX Excellos La Rochelle, France	59.0	—	—	—	0 programs
41	CZ Cellex Cell Professionals Cologne, Germany	59.0	—	—	—	0 programs
42	AM Anemocyte Gerenzano, IT	59.0	—	—	—	0 programs
43	CV CEVEC Pharmaceuticals Cologne, Germany	56.5	—	—	—	0 programs
44	CX CellGenix Freiburg, DE	56.5	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Cell & Gene Therapy CDMO

Integrated vs point-solution CDMO

Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.

Regulatory record by process class

Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.

Chain-of-identity + cold chain

Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.

Commercial track record

For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

Cell & Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Cell & Gene Therapy CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Cell & Gene Therapy CDMOs include Novartis, Takeda, Merck KGaA / MilliporeSigma (CDMO). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Cell & Gene Therapy CDMOs have FDA inspection records?

CDMO Signal tracks 15 Cell & Gene Therapy CDMOs with FDA inspection records and 279 EMA/MHRA GMP certificates across the group.

What should I look for in a cell and gene therapy CDMO?

Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.

How many cell and gene therapy CDMOs does CDMO Signal track?

109 CDMOs are tracked as cell or gene therapy manufacturers — the union of cell therapy, AAV, lentiviral, adenoviral, and gene therapy-tagged CDMOs. This is the broadest advanced-therapy candidate list on our platform.

Related modalities

Cell Therapy CDMOs AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Gene Therapy CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Viral Vector